#ProudToShare: #Biocon’s Head of Supply Chain, Procurement, and Contract Manufacturing Vishal Nayyar has been honoured with the Champion of #SupplyChain #award at the Supply Chain & Logistics Conclave 2025 held in New Delhi. Selected after a rigorous evaluation of over 300 senior professionals across industries, the recognition celebrates Vishal’s exemplary contributions in driving innovation, digital transformation, sustainability, and strategic impact in the supply chain ecosystem. Congratulations!
About us
Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.
- Website
-
http://www.biocon.com
External link for Biocon
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Bangalore, Karnataka
- Type
- Public Company
Locations
-
Primary
Hosur Road, Electronics City
Bangalore, Karnataka 560100, IN
Employees at Biocon
Updates
-
#Walkin: #Biocon Limited has partnered with #MSDESkillIndia to recruit #apprentices in #Kolar under the National Apprenticeship Promotion Scheme. Selected candidates will receive extensive training, which may be followed by a full-time employment #opportunity based on available vacancies at the time.
-
-
#ProudToShare: #Biocon’s Hyderabad site has been recognized at the 24th Global Environment & Sustainability Awards organized by #GreentechFoundation. Winning in the category of ‘Innovative Environment Technology Adoption’, it is a testament to the Company's continued efforts towards natural resource #conservation, #carbonfootprint reduction and waste minimisation through innovative technologies.
-
-
Biocon reposted this
Biocon Academy is currently accepting applications for its 16-week intensive Syngene Ramaiah Certificate Program in Sterile Manufacturing – Batch 3, specially designed for graduates in Biochemistry, Biotechnology, Microbiology and Pharmacy. Get hands-on training, industry exposure, and placement support to jumpstart your career in sterile manufacturing. 👉 To learn more and apply: https://lnkd.in/gq5XdAEa #biosciences #biotech #biotechnology #careers #freshers #jobs #pharma #talent #upskilling
-
-
Did you know that #braintumour can often go unnoticed until they reach an advanced stage? That there are more than 120 different types of tumours that can develop in the brain? In an informative session attended by several #Bioconites, Dr Komal Prasad from Narayana Hrudayalaya helped understand key concepts and dispel common myths around the condition.
-
-
Achieving #genderequality should be recognized as not just as a #women’s issue, but one that is relevant to #men as well. Challenging accepted notions of #masculinity and subsequent gender roles, thus, is essential for creating a more equitable and #inclusive society. In a deep dive, psychologist Dr Anna Varghese recently took #Bioconites through a powerful and engaging session.
-
-
#100MillionsMilestone #DriversOfChange #BioconMalaysia Working for #BioconBiologics, a Top 10 Global Biotech Employer, is not just work, because each day, every employee works with a purpose and pride. The pride of being a part of Malaysia’s first biopharma injectables facility with a purpose of addressing the growing needs of diabetes patients in Malaysia, and across the world. Together, we are not just enabling affordable access to insulins– we are also transforming healthcare and patients’ lives, one breakthrough at a time. Since entering the Malaysian market in 2016, Biocon Biologics has played a pivotal role in transforming diabetes management, and has supplied over 100 million cartridges of rh-insulin serving over 345,000 patients in Malaysia. #Malaysia #JohorBahru #Purpose #AccessToInsulins #transforminghealthcare Seema Ahuja Joe Sian Rinat Livne PAT THONG Alolika Chakrabortti, Ph.D. Kavita Rao, Ph.D, MBA Sugeetha Kersenernayer Ratish Trehan Susheel Umesh Pankaj Gupta
-
#ProudToShare: #Biocon has been awarded a #Gold rating in the 2024 #EcoVadis Corporate #Sustainability Assessment, with our score progressing from 70 to 77 — placing us in the top 5% of companies assessed worldwide. Our highest rating to date, it is a testament to our commitment to sustainable growth and continuous improvement. ARUN GUPTA
-
-
#WelcomeToBiocon: Always excited to welcome new #Bioconites to the team! Congratulations, and we look forward to you contributing to our purpose of providing everyone, everywhere, affordable access to medicines. #Biocon
-
-
Do you know what Kiran Mazumdar Shaw calls the most interesting project in her journey? In this compelling interview with The Medicine Maker, she shares insights into a pathbreaking initiative that could transform cancer treatment, especially for head and neck cancers. The story also delves into her journey of building #Biocon into a purpose-led #biopharmaceutical company, driven by the mission to make advanced therapies accessible to patients around the world. Kiran Mazumdar-Shaw has been featured in The Medicine Maker Power List since 2015. This exclusive interview is part of the 2025 edition. Read the full article: https://lnkd.in/e-UstxMd Seema Ahuja Biocon Biocon Biologics Syngene International Limited